J 2021

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

PAGANO, L., J. SALMANTON-GARCIA, F. MARCHESI, A. BUSCA, P. CORRADINI et. al.

Basic information

Original name

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Authors

PAGANO, L. (guarantor), J. SALMANTON-GARCIA, F. MARCHESI, A. BUSCA, P. CORRADINI, M. HOENIGL, N. KLIMKO, P. KOEHLER, A. PAGLIUCA, F. PASSAMONTI, L. VERGA, B. VISEK, O. ILHAN, G. NADALI, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), R. CORDOBA-MASCUNANO, M. MARCHETTI, G. P. COLLINS, F. FARINA, C. CATTANEO, A. CABIRTA, M. GOMES-SILVA, F. ITRI, J. VAN DOESUM, M. P. LEDOUX, M. CERNAN, O. JAKSIC, R. F. DUARTE, G. MAGLIANO, A. S. OMRANI, N. S. FRACCHIOLLA, A. KULASEKARARAJ, T. VALKOVIC, C. B. POULSEN, M. MACHADO, A. GLENTHOJ, I. STOMA, Zdenek RACIL (203 Czech Republic), K. PIUKOVICS, Milan NAVRATIL, Z. EMARAH, U. SILI, J. MAERTENS, O. BLENNOW, R. BERGANTIM, C. GARCIA-VIDAL, L. PREZIOSO, A. GUIDETTI, M. I. DEL PRINCIPE, M. POPOVA, N. DE JONGE, I. ORMAZABAL-VELEZ, N. FERNANDEZ, I. FALCES-ROMERO, A. CUCCARO, S. MEERS, C. BUQUICCHIO, D. ANTIC, M. AL-KHABORI, R. GARCIA-SANZ, M. M. BIERNAT, M. C. TISI, E. SAL, L. RAHIMLI, N. COLOVIC, M. SCHONLEIN, M. CALBACHO, C. TASCINI, C. MIRANDA-CASTILLO, N. KHANNA, G. A. MENDEZ, V. PETZER, J. NOVAK, C. BESSON, R. DULERY, S. LAMURE, M. NUCCI, G. ZAMBROTTA, Pavel ZAK (203 Czech Republic), G. C. SEVAL, V. BONUOMO, Jiří MAYER (203 Czech Republic, belonging to the institution), A. LOPEZ-GARCIA, M. V. SACCHI, S. BOOTH, F. CICERI, M. OBERTI, M. SALVINI, M. IZUZQUIZA, R. NUNES-RODRIGUES, E. AMMATUNA, Ales OBR (203 Czech Republic), R. HERBRECHT, L. NUNEZ-MARTIN-BUITRAGO, V. MANCINI, H. SHWAYLIA, M. SCIUME, J. ESSAME, M. NYGAARD, J. BATINIC, Y. GONZAGA, I. REGALADO-ARTAMENDI, L. K. KARLSSON, M. SHAPETSKA, Michaela HANAKOVA (203 Czech Republic), S. EL-ASHWAH, Z. BORBENYI, G. M. COLAK, A. NORDLANDER, G. DRAGONETTI, A. M. E. MARAGLINO, A. RINALDI, C. DE RAMON-SANCHEZ and O. A. CORNELY

Edition

JOURNAL OF HEMATOLOGY & ONCOLOGY, LONDON, BMC, 2021, 1756-8722

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 23.168

RIV identification code

RIV/00216224:14110/21:00122744

Organization unit

Faculty of Medicine

UT WoS

000707341700001

Keywords in English

COVID-19; Pandemic; Hematological malignancies; Epidemiology; EHA

Tags

Tags

International impact, Reviewed
Změněno: 5/11/2021 09:44, Mgr. Tereza Miškechová

Abstract

V originále

Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March-May 2020) and the second wave (October-December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.

Links

2015-1-CZ01-KA203-013935, interní kód MU
Name: Medical Curriculum Innovations (Acronym: MEDCIN)
Investor: European Union, Strategic Partnerships in the field of education, training and youth